newsfilter
← Earnings
Earnings Releases·

SINTX Technologies — Third Quarter 2026 Earnings Summary

  • Revenue surged more than tenfold to $2.2 million for the quarter ended September 30, 2026, compared to $208,000 in the prior-year period, while net loss narrowed 55% to $1.6 million and gross margin expanded to 62%.
  • The company regained Nasdaq compliance with total stockholders' equity rising to $3.39 million and secured approximately $2.0 million in proceeds from warrant exercises following the achievement of the $2 million revenue milestone.
  • Commercialization of the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System is underway, with large-animal in vivo studies for wound care applications expected to conclude in Q1 2027.
  • Management expressed confidence in pursuing growth opportunities in 2027, focusing on operating efficiencies and additional financing alternatives to support commercialization and preclinical development.
Company
SINTX TECHNOLOGIES INC
Sector
Healthcare
Industry
Medical Devices